Back to Search
Start Over
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
- Source :
-
Blood [Blood] 2015 Apr 02; Vol. 125 (14), pp. 2306-9. - Publication Year :
- 2015
- Subjects :
- Adenine analogs & derivatives
Antineoplastic Agents pharmacology
Antineoplastic Combined Chemotherapy Protocols
Apoptosis drug effects
Blotting, Western
Cell Proliferation drug effects
Drug Synergism
Flow Cytometry
Humans
Leukemia, Lymphocytic, Chronic, B-Cell metabolism
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Lymphoma, Mantle-Cell metabolism
Lymphoma, Mantle-Cell pathology
Piperidines
Tumor Cells, Cultured
Cell Adhesion drug effects
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Lymphoma, Mantle-Cell drug therapy
Proto-Oncogene Proteins c-bcr metabolism
Purines pharmacology
Pyrazoles pharmacology
Pyrimidines pharmacology
Quinazolinones pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 125
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Report
- Accession number :
- 25838279
- Full Text :
- https://doi.org/10.1182/blood-2014-12-619163